With the release of the first JCA report (Tovorafenib in pediatric low-grade glioma), the industry is getting its first real look at how the new European framework will be navigated.
The submitted evidence base is notably thin, yielding only one assessable PICO comparison. But a close reading of the exchanges between the EU assessors and the manufacturer reveals that this may not have been an oversight; it may be a masterclass in lane-management.
The Asymmetric Risk of the JCA
The new HTA regulation created a structural misalignment: it centralises clinical assessment but leaves pricing and reimbursement strictly national. For a manufacturer, this creates an asymmetric risk profile. A harsh, pan-European critique in Brussels becomes an irreversible liability across all 27 member states.
Faced with this, the strategic imperative is clear: minimise EU exposure to maximise local optionality.
The Evidence from the Report
The official JCA report documents this strategy in real-time. When EU assessors explicitly requested the pooling of two trial arms (Arm 1 and Arm 2) to strengthen the comparative efficacy analysis, the manufacturer formally declined, citing a lack of "full source data verification" in the second arm.
Similarly, collected health-related Quality of Life (HRQoL) data was kept out of the comparative assessment entirely, having been classified to the EMA as strictly "exploratory."
While a patient representative rightly noted in the report that this creates a "major evidence gap" for families, from a market access perspective, the manufacturer's logic is clear. Why volunteer fragile, single-arm utility data to an EU assessment where it can only be used descriptively, risking a devastating pan-European critique?
A Bet on Local Accountability
Instead, the manufacturer bypasses the centralised, technocratic layer in Brussels in favour of local democracy.
They understand that true accountability to patients and families does not sit with an EU committee; it sits with national ministers, payers, and clinicians. By withholding their most sensitive value-based arguments, they are forcing the actual debate to happen at the 27 national tables where local health systems weigh cost, benefit, and patient experience on their own terms.
We will know this strategy is confirmed if the pooled efficacy data and HRQoL evidence that Brussels never saw surfaces in the 2026–27 national dossiers (HAS, NICE, G-BA) to successfully secure reimbursement.
The Structural Question for Policymakers
But this raises a critical question for policymakers. If the structural design of the JCA incentivises drugmakers to systematically under-invest in the joint dossier to protect their national negotiating power, we must question the relevance of the process moving forward.
If the system makes bypassing it the most rational choice, the JCA risks becoming a mere administrative gate, rather than the cornerstone of European patient access it was designed to be.